STAAR SURGICAL COMPANY

NASDAQ: STAA (STAAR Surgical Company)

Kemas kini terakhir: 2 hari lalu, 6:29AM

19.04

-0.07 (-0.37%)

  • 1H -0.37%
  • 5H -9.20%
  • 1B -17.97%
  • 6B 5.19%
  • Tahun Ke Tarikh -19.32%
  • 1T -20.57%
  • 5T -82.16%
Penutupan Terdahulu 19.11
Buka 19.09
Jumlah Dagangan 893,356
Purata Dagangan (3B) 1,340,614
Modal Pasaran 939,927,744
Harga / Pendapatan (P/E Ke hadapan) 50.25
Harga / Jualan (P/S) 4.10
Harga / Buku (P/B) 2.67
Julat 52 Minggu
13.50 (-29%) — 30.81 (61%)
Tarikh Pendapatan 5 Nov 2025
Margin Keuntungan -25.46%
Margin Operasi (TTM) -81.43%
EPS Cair (TTM) -1.44
Pertumbuhan Hasil Suku Tahunan (YOY) -44.90%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 107.20%
Jumlah Hutang/Ekuiti (D/E MRQ) 10.48%
Nisbah Semasa (MRQ) 4.78
Aliran Tunai Operasi (OCF TTM) -11.69 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 10.73 M
Pulangan Atas Aset (ROA TTM) -5.90%
Pulangan Atas Ekuiti (ROE TTM) -19.14%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Medical Instruments & Supplies (US) Menaik Bercampur
Medical Instruments & Supplies (Global) Menaik Menurun
Stok STAAR Surgical Company Menurun Menaik

AISkor Stockmoo

-1.8
Konsensus Penganalisis 1.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal -3.5
Osilator Teknikal -2.5
Purata -1.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
STAA 940 M - - 2.67
MMSI 5 B - 44.30 3.20
ATRC 2 B - - 4.08
LMAT 2 B 0.94% 36.64 5.13
AZTA 2 B - 63.00 1.07
PLSE 970 M - - 11.03

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
Sektor Healthcare
Industri Medical Instruments & Supplies
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 0.64%
% Dimiliki oleh Institusi 109.43%

Pemilikan

Nama Tarikh Syer Dipegang
Broadwood Capital Inc 30 Sep 2025 13,519,491
Yunqi Capital Ltd 30 Sep 2025 2,500,061
Sand Grove Capital Management Llp 30 Sep 2025 829,123
American Capital Management Inc 30 Sep 2025 743,424
Defender Capital, Llc. 31 Dec 2025 668,222
Water Island Capital Llc 30 Sep 2025 658,317
Julat 52 Minggu
13.50 (-29%) — 30.81 (61%)
Julat Harga Sasaran
21.50 (12%) — 30.75 (61%)
Tinggi 30.75 (Wells Fargo, 61.50%) Pegang
Median 22.00 (15.55%)
Rendah 21.50 (Jefferies, 12.92%) Beli
Purata 24.75 (29.99%)
Jumlah 1 Beli, 2 Pegang
Harga Purata @ Panggilan 21.33
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Jefferies 28 Jan 2026 21.50 (12.92%) Beli 19.04
Canaccord Genuity 16 Jan 2026 22.00 (15.55%) Pegang 20.97
10 Dec 2025 30.75 (61.50%) Pegang 23.99
Wells Fargo 10 Dec 2025 30.75 (61.50%) Pegang 23.99

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
15 Jan 2026 Pengumuman STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
06 Jan 2026 Pengumuman Alcon Terminates Agreement to Acquire STAAR Surgical
06 Jan 2026 Pengumuman Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon
06 Jan 2026 Pengumuman STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders
19 Dec 2025 Pengumuman Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
19 Dec 2025 Pengumuman Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
17 Dec 2025 Pengumuman Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
17 Dec 2025 Pengumuman Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
17 Dec 2025 Pengumuman STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
16 Dec 2025 Pengumuman Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
16 Dec 2025 Pengumuman Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
16 Dec 2025 Pengumuman Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
15 Dec 2025 Pengumuman Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
12 Dec 2025 Pengumuman Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
11 Dec 2025 Pengumuman Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
11 Dec 2025 Pengumuman STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
10 Dec 2025 Pengumuman Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer
09 Dec 2025 Pengumuman Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical
09 Dec 2025 Pengumuman Alcon Announces Amended Merger Agreement with STAAR Surgical
08 Dec 2025 Pengumuman Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process
08 Dec 2025 Pengumuman Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
08 Dec 2025 Pengumuman STAAR Surgical Announces Expiration of Go-Shop Period
02 Dec 2025 Pengumuman Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
10 Nov 2025 Pengumuman Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
07 Nov 2025 Pengumuman STAAR Surgical Announces Amendments to Alcon Merger Agreement
06 Nov 2025 Pengumuman Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
05 Nov 2025 Pengumuman STAAR Surgical Reports Third Quarter 2025 Results
04 Nov 2025 Pengumuman Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
04 Nov 2025 Pengumuman Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
31 Oct 2025 Pengumuman Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda